It covers genes that are informative for the use of FDA-approved therapies in non-small cell lung cancer (EGFR, BRAF, ALK, ROS1), colorectal cancer (KRAS, NRAS, BRAF), breast cancer (PIK3CA), and bladder cancer (FGFR2/3). CSTP is intended for the analysis of solid tumors from patients with clinically advanced disease (stage III or IV). The test can detect microsatellite instability and provides an estimate of tumor mutation burden (TMB). The GeneTrails ® Comprehensive Solid Tumor Panel (CSTP) is a next-generation sequencing (NGS) test comprised of two amplicon-based libraries (one DNA, one RNA/cDNA) used to screen for clinically informative gene alterations that are important in making therapeutic decisions, including SNVs, in/dels, copy number alterations and gene fusion events. GeneTrails® Solid Tumor Fusion Gene panel (RNA sequencing panel).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |